ARQL Lifts 2018 Outlook, AXGN Q2 Revenue Up 36%, RXII Catches Eyes

Today's Daily Dose brings you news about BioCryst Pharma's stock offering; AxoGen and Blueprint Medicines' strong Q2 financial results; positive results of RXi Pharmaceuticals' phase I/II trial with RXI-109 for retinal scarring and reverse stock split of Synthetic Biologics.

from RTT - Biotech https://ift.tt/2McqE5N
via IFTTT